
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    1. Key functional markers and pathways<br><br>I‚Äôll first group the most informative genes by function, with brief roles:<br><br>**A. Innate immune / myeloid activation & inflammation**<br>- **FCN1** ‚Äì Ficolin-1, classical marker of inflammatory monocytes; high in non-classical/activated monocytes/macrophages.<br>- **S100A8, S100A9, S100A12** ‚Äì Calcium-binding proteins, hallmark of inflammatory monocytes/neutrophil-like myeloid cells; strong alarmins.<br>- **FPR2, FPR3** ‚Äì Formyl peptide receptors; chemotactic GPCRs enriched in activated monocytes/macrophages and neutrophils.<br>- **MCEMP1** ‚Äì Mast cell‚Äìexpressed membrane protein 1, but in scRNA-seq often marks highly activated inflammatory monocytes/macrophages.<br>- **AQP9** ‚Äì Aquaporin 9, enriched in myeloid cells, especially activated monocytes/macrophages.<br>- **APOBEC3A** ‚Äì Cytidine deaminase, strongly induced in inflammatory monocytes/macrophages (e.g., IFN-stimulated, pro-inflammatory states).<br>- **RETN (Resistin)** ‚Äì Secreted inflammatory mediator, high in activated monocytes/macrophages.<br>- **SPP1 (Osteopontin)** ‚Äì Secreted cytokine/ECM protein; hallmark of ‚ÄúSPP1+‚Äù inflammatory/activated macrophages and disease-associated microglia-like states.<br>- **IL1RN** ‚Äì IL-1 receptor antagonist; anti-inflammatory feedback, but typically upregulated in activated myeloid cells.<br>- **IL4I1** ‚Äì L-phenylalanine oxidase, immunoregulatory enzyme in antigen-presenting myeloid cells.<br>- **PLA2G7** ‚Äì Platelet-activating factor acetylhydrolase; expressed in monocytes/macrophages, linked to inflammatory lipid metabolism.<br>- **SERPINA1** ‚Äì Alpha-1 antitrypsin; acute-phase reactant, often up in activated myeloid cells.<br>- **SLAMF8** ‚Äì Myeloid receptor, enriched in activated macrophages and inflammatory monocytes.<br>- **RNASE2** ‚Äì Eosinophil-derived neurotoxin; but also seen in activated monocytes/macrophages.<br><br>**B. Phagocytosis, complement, Fc receptors**<br>- **CR1** ‚Äì Complement receptor 1; phagocytic receptor on monocytes/macrophages.<br>- **FCGR2A (CD32A)** ‚Äì Activating FcŒ≥ receptor; classical monocyte/macrophage marker.<br>- **FCGR3A (CD16)** ‚Äì FcŒ≥RIIIa; marks non-classical/intermediate monocytes and some macrophage subsets.<br>- **FCER1G** ‚Äì Fc receptor gamma chain; signaling adaptor for multiple Fc and innate receptors.<br>- **MARCO** ‚Äì Scavenger receptor; hallmark of tissue-resident and/or specialized macrophages (e.g., border-associated macrophages, perivascular macrophages, some microglia subsets).<br>- **CLEC12A** ‚Äì C-type lectin receptor; expressed on monocytes, dendritic cells, some macrophages.<br>- **CLEC5A** ‚Äì DAP12-associated C-type lectin; pro-inflammatory myeloid receptor.<br>- **SIGLEC1 (CD169)** ‚Äì Sialoadhesin; classic marker of specialized macrophages (e.g., perivascular, meningeal, subcapsular sinus macrophages).<br>- **SIGLEC12** ‚Äì Siglec family member; myeloid-associated.<br>- **TREM1** ‚Äì Triggering receptor expressed on myeloid cells 1; amplifies inflammatory responses in monocytes/macrophages.<br>- **TYROBP (DAP12)** ‚Äì ITAM-bearing adaptor for TREM2, CLEC5A, etc.; core myeloid signaling component.<br><br>**C. Antigen presentation / HLA**<br>- **HLA-DRA, HLA-DRB5** ‚Äì MHC class II; antigen-presenting myeloid cells (monocytes, macrophages, dendritic cells).<br>- **LILRA5, LILRA6, LILRB2** ‚Äì Leukocyte immunoglobulin-like receptors; inhibitory/activating receptors on monocytes/macrophages and dendritic cells.<br>- **CD300E, CD300LF** ‚Äì Immunoregulatory receptors on myeloid cells.<br><br>**D. Classical monocyte / macrophage core markers**<br>- **CD14** ‚Äì Co-receptor for LPS; hallmark of classical monocytes and many macrophages.<br>- **LYZ** ‚Äì Lysozyme; pan-myeloid (monocytes, macrophages, neutrophils).<br>- **SLC11A1 (NRAMP1)** ‚Äì Phagosomal metal transporter; enriched in monocytes/macrophages.<br>- **SLC16A10** ‚Äì Amino acid transporter; seen in myeloid cells.<br>- **HK3** ‚Äì Hexokinase 3; glycolytic enzyme enriched in myeloid lineage.<br>- **FBP1** ‚Äì Fructose-1,6-bisphosphatase; metabolic enzyme, sometimes up in specific myeloid subsets.<br><br>**E. Chemokines / cytokines**<br>- **CCL18** ‚Äì Chemokine associated with alternatively activated/tissue macrophages, including perivascular and meningeal macrophages in brain.<br>- **CCL13** ‚Äì Chemokine produced by monocytes/macrophages, often in tissue/inflammatory contexts.<br>- **EREG (Epiregulin)** ‚Äì EGFR ligand; produced by activated macrophages, associated with tissue remodeling and inflammation.<br><br>**F. Other / non-coding / less specific**<br>- **ST14** ‚Äì Matriptase; serine protease, can be expressed in some myeloid subsets.<br>- **SDS** ‚Äì Serine dehydratase; metabolic.<br>- **MMP2-AS1** ‚Äì Antisense to MMP2; non-coding.<br>- **SMIM25, PARAL1, LINC02345** ‚Äì Less characterized, but appear in myeloid transcriptional programs.<br><br>Overall, this is a strongly **innate myeloid, phagocytic, inflammatory, antigen-presenting** signature.<br><br>---<br><br>2. Key cell type‚Äìdefining markers (tissue context)<br><br>Within brain tissue, the main myeloid populations are **microglia** and **non-parenchymal macrophages/monocytes** (perivascular, meningeal, choroid plexus, infiltrating blood monocytes).<br><br>**Markers arguing against parenchymal microglia:**<br>- Canonical microglia markers (e.g., **P2RY12, TMEM119, CX3CR1, TREM2, GPR34, SALL1**) are **absent** from the top markers.<br>- Instead, we see strong **FCN1, S100A8/A9/A12, RETN, APOBEC3A, CLEC12A, CD14, FCGR3A**, which are **classical/inflammatory monocyte** markers and are typically low/absent in homeostatic microglia.<br>- **SIGLEC1, MARCO, CCL18** are more characteristic of **border-associated macrophages (BAMs)** and infiltrating monocyte-derived macrophages than of homeostatic microglia.<br><br>**Markers supporting monocyte / macrophage identity:**<br>- **FCN1, CD14, LYZ, S100A8/A9/A12, FCGR2A, FCGR3A, CLEC12A, SLC11A1, APOBEC3A, RETN, PLA2G7, IL1RN, TREM1, SLAMF8** ‚Äì classic blood monocyte / inflammatory macrophage signature.<br>- **HLA-DRA, HLA-DRB5, LILR family, CD300 family** ‚Äì strong antigen-presenting myeloid cell profile.<br>- **SPP1, MARCO, SIGLEC1, CCL18** ‚Äì typical of **tissue-resident or monocyte-derived macrophages** in barrier tissues, including brain border regions.<br><br>In human brain scRNA-seq atlases (e.g., Olah et al., 2020; Van Hove et al., 2019; Sankowski et al., 2019; recent human brain immune atlases), this combination is characteristic of **non-parenchymal macrophages and/or infiltrating monocytes**, not microglia.<br><br>---<br><br>3. Cross-referencing with scRNA-seq databases / literature<br><br>Using known references:<br><br>- **Human blood monocytes** (e.g., Villani et al. 2017; Monaco et al. 2019):<br>  - **FCN1+, S100A8/A9/A12+, LILRA5+, CLEC12A+, CD14+, LYZ+, APOBEC3A+, RETN+, PLA2G7+** define classical/inflammatory monocytes.<br>  - **FCGR3A+** marks non-classical/intermediate monocytes.<br>  - This cluster shows a **hybrid of classical (CD14high, FCN1high, S100A8/A9/A12high) and FCGR3A+ features**, consistent with activated/inflammatory monocytes and monocyte-derived macrophages.<br><br>- **Human brain immune atlases**:<br>  - **Microglia**: P2RY12+, TMEM119+, CX3CR1+, SALL1+, low FCN1/S100A8/A9.<br>  - **Perivascular/meningeal macrophages (BAMs)**: **CD163+, MRC1 (CD206)+, SIGLEC1+, CCL18+, MARCO+**, often HLA-DRhigh, and can express SPP1.<br>  - **Infiltrating monocytes/macrophages** in pathology: **FCN1+, S100A8/A9/A12+, APOBEC3A+, RETN+, TREM1+, CLEC12A+, CD14+, FCGR3A+**, often SPP1+.<br><br>The current signature is **much closer to inflammatory monocytes / monocyte-derived macrophages** than to homeostatic BAMs (which are more CD163/MRC1/LYVE1/SEPP1) or microglia.<br><br>However, **SIGLEC1, MARCO, CCL18, SPP1** are strongly associated with **tissue/border-associated macrophages** in the CNS, suggesting these are not just circulating monocytes but **brain-associated monocyte-derived macrophages** or **BAM-like macrophages** in an inflammatory state.<br><br>---<br><br>4. Most probable general cell type<br><br>Given:<br><br>- Strong **myeloid** identity (LYZ, CD14, FCGR2A/3A, SLC11A1, TYROBP, HLA-II).<br>- Strong **inflammatory monocyte** signature (FCN1, S100A8/A9/A12, APOBEC3A, RETN, TREM1, CLEC12A).<br>- Presence of **tissue macrophage markers** (SPP1, MARCO, SIGLEC1, CCL18).<br><br>The most probable **general cell type** in human brain tissue is:<br><br>> **Myeloid cell ‚Äì monocyte / macrophage lineage (non-microglial brain myeloid cell).**<br><br>More specifically, these are **inflammatory monocytes / monocyte-derived macrophages** associated with brain tissue (e.g., perivascular/meningeal/infiltrating macrophages), not parenchymal microglia.<br><br>---<br><br>5. Top 3 most probable sub cell types (ranked)<br><br>Within the myeloid compartment of brain tissue, the three most plausible subtypes:<br><br>### 1) Inflammatory monocyte-derived macrophages in brain (most likely)<br><br>**Rationale:**<br>- Strong **FCN1high, S100A8/A9/A12high, APOBEC3Ahigh, RETNhigh, CLEC12A+, TREM1+, SLAMF8+** ‚Äì canonical inflammatory monocyte signature.<br>- **SPP1+, MARCO+, SIGLEC1+, CCL18+** ‚Äì indicate **tissue adaptation** and macrophage differentiation, consistent with monocytes that have entered brain and differentiated into macrophages (e.g., perivascular/infiltrating).<br>- **HLA-DRhigh, LILR+, CD300+** ‚Äì antigen-presenting, immunoregulatory macrophage phenotype.<br>- This combination is typical of **monocyte-derived macrophages in neuroinflammatory conditions** (e.g., MS lesions, brain tumors, injury), often annotated as **‚ÄúFCN1+ / SPP1+ inflammatory macrophages‚Äù** or **‚Äúmonocyte-derived macrophages‚Äù** in human brain scRNA-seq.<br><br>**Annotation label (most precise):**<br>> **Monocyte-derived inflammatory macrophages (brain-associated)**<br><br>---<br><br>### 2) Classical/inflammatory blood-derived monocytes infiltrating brain<br><br>**Rationale:**<br>- The **very strong FCN1, S100A8/A9/A12, APOBEC3A, RETN, CLEC12A, CD14, LYZ** profile is essentially that of **classical inflammatory monocytes**.<br>- **FCGR3A** suggests some intermediate/non-classical features, but the FCN1/S100A8/A9/A12 axis is dominant.<br>- If the dataset includes vascular/blood contamination or early infiltrating cells, these could be **circulating or recently extravasated monocytes**.<br><br>What makes this slightly less likely than #1 is the presence of **SPP1, MARCO, SIGLEC1, CCL18**, which are more typical of **tissue-adapted macrophages** rather than purely circulating monocytes.<br><br>**Annotation label:**<br>> **Inflammatory (FCN1+) monocytes / early infiltrating monocytes**<br><br>---<br><br>### 3) Brain border-associated macrophages (perivascular/meningeal macrophages)<br><br>**Rationale:**<br>- **SIGLEC1, MARCO, CCL18, SPP1** are all compatible with **border-associated macrophages (BAMs)**.<br>- BAMs are non-parenchymal macrophages at the meninges, perivascular spaces, and choroid plexus.<br>- However, canonical BAM markers (e.g., **CD163, MRC1/CD206, LYVE1, SEPP1**) are not in the top list, and the **FCN1/S100A8/A9/A12/APOBEC3A** inflammatory monocyte signature is stronger than typically seen in steady-state BAMs.<br>- This suggests a **BAM-like macrophage** but in a **highly inflammatory, monocyte-derived state**, which overlaps heavily with #1.<br><br>**Annotation label:**<br>> **Inflammatory border-associated macrophages (BAM-like)**<br><br>---<br><br>**Most likely subtype (final choice)**<br><br>Given the combination of:<br><br>- Strong **inflammatory monocyte** markers (FCN1, S100A8/A9/A12, APOBEC3A, RETN, CLEC12A, TREM1).<br>- Strong **tissue macrophage** markers (SPP1, MARCO, SIGLEC1, CCL18).<br>- Absence of **microglia core markers** (P2RY12, TMEM119, CX3CR1, SALL1).<br><br>The most likely annotation is:<br><br>> **Monocyte-derived inflammatory macrophages (non-parenchymal brain myeloid cells; FCN1+/SPP1+ inflammatory macrophages).**<br><br>If you need a concise label for a cell type column:<br><br>- **General:** ‚ÄúMyeloid ‚Äì monocyte/macrophage‚Äù<br>- **Specific:** ‚ÄúMonocyte-derived inflammatory macrophage (FCN1+/SPP1+)‚Äù<br><br>---<br><br>6. Concise summary<br><br>- The marker set is unequivocally **myeloid**, with strong **inflammatory monocyte** features (FCN1, S100A8/A9/A12, APOBEC3A, RETN, CLEC12A, CD14, LYZ) and **antigen-presenting** capacity (HLA-DRA/DRB5, LILR, CD300).<br>- Co-expression of **SPP1, MARCO, SIGLEC1, CCL18** indicates **tissue-adapted macrophages** rather than purely circulating monocytes.<br>- Absence of canonical microglia markers rules out parenchymal microglia.<br>- In the context of human brain scRNA-seq, this profile best matches **monocyte-derived inflammatory macrophages** associated with brain borders or lesions.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Myeloid ‚Äì monocyte/macrophage lineage (non-microglial brain myeloid cell)</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Monocyte-derived inflammatory macrophages (brain-associated; FCN1+/SPP1+ inflammatory macrophages)</li><li>Inflammatory (FCN1+) monocytes / early infiltrating monocytes</li><li>Inflammatory border-associated macrophages (BAM-like)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Inflammatory monocytes mixed with monocyte-derived macrophages</li><li>Monocyte-derived inflammatory macrophages mixed with border-associated macrophages</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">nan</div>
                        <div class="scoring-content">
                            Error: Error code: 400 - {'error': {'message': "Unsupported parameter: 'max_tokens' is not supported with this model. Use 'max_completion_tokens' instead.", 'type': 'invalid_request_error', 'param': 'max_tokens', 'code': 'unsupported_parameter'}}<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    